Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Should You Sell?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped down before the market opened on Friday . The stock had previously closed at $14.42, but opened at $13.62. Astellas Pharma shares last traded at $13.9350, with a volume of 11,430 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Astellas Pharma Stock Performance

The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17. The company has a market capitalization of $24.78 billion, a price-to-earnings ratio of 12.75 and a beta of 0.07. The company’s fifty day simple moving average is $13.43 and its two-hundred day simple moving average is $14.64.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. The business had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%. Equities research analysts predict that Astellas Pharma Inc. will post 1.25 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).